Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildacerfont in classic congenital adrenal hyperplasia
NCT04544410Phase 2Terminated
- Sponsor
- Spruce Biosciences, Inc.
- Start
- Feb 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in congenital adrenal hyperplasia (CAH) comparing Tildacerfont Group with Placebo (2 arms). Primary endpoint: Change in Total Daily Glucocorticoid Dose at 24 weeks. Started Feb 2021; status: terminated.
02
Drugs
tildacerfont
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT04544410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544410.